工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor-Infiltrating CD45RO(+) Memory Cells Are Associated with Favorable Prognosis in Oral Squamous Cell Carcinoma Patients.
Tumor-Infiltrating CD45RO(+) Memory Cells Are Associated with Favorable Prognosis in Oral Squamous Cell Carcinoma Patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD45RO 表达 TILs 的高比例与 OSCC 患者的无病/总生存期改善相关。此外,表达 CD45RO 的 TILs 数量与肿瘤中 MICA 的表达相关。这些结果表明,表达 CD45RO 的 TILs 是 OSCC 的有用生物标志物。
TIL(肿瘤浸润淋巴细胞)(TILs)已被用于预测实体瘤的预后。在本研究中,我们探讨了TILs中的哪些分子在口腔鳞状细胞癌(OSCC)患者的预后中发挥作用。
在一项回顾性病例对照研究中,我们通过免疫组化评估了33例OSCC患者中CD3、CD8、CD45RO、Granzyme B以及组织相容性复合体I类链相关分子A(MICA)的表达,作为预后预测因素。根据中央肿瘤(CT)和浸润边缘(IM)中每种分子的TILs数量,将患者分为TILs高或TILs低。此外,根据染色强度确定MICA表达评分。
非复发组中CD45RO + /TIL在CT和IM区域显著高于复发组(p < 0.05)。CT和IM区域CD45RO + /TILs低水平组以及IM区域Granzyme B + /TILs低水平组的无病生存期/总生存率分别显著低于CD45RO + /TILs高水平组和Granzyme B + /TILs高水平组(p < 0.05)。此外,CD45RO + /TILs高水平组周围肿瘤的MICA表达评分显著高于CD45RO + /TILs低水平组(p < 0.05)。
Tumor-infiltrating lymphocytes (TILs) have been used to predict the prognosis of solid tumors. In this study, we investigated which molecules in TILs play a role in the prognosis of patients with oral squamous cell carcinoma (OSCC).
In a retrospective case-control study, we immunohistochemically evaluated the expression of CD3, CD8, CD45RO, Granzyme B, and the major histocompatibility complex class I chain-related molecule A (MICA) of the histocompatibility complex as predictors of prognosis in 33 patients with OSCC. The patients were classified as TILs High or TILs Low according to the number of TILs for each molecule in the central tumor (CT) and invasive margin (IM). Furthermore, MICA expression scores were determined based on the intensity of the staining.
CD45RO + /TIL in the nonrecurrent group were significantly higher than those in the recurrent group in the CT and IM areas ( p < 0.05). The disease-free survival/overall survival rate of the CD45RO + /TILs Low group in the CT and IM areas and the Granzyme B + /TILs Low group in the IM area was significantly lower than that of the CD45RO + /TILs High group and the Granzyme B + /TILs High group, respectively ( p < 0.05). Furthermore, the MICA expression score of tumors around the CD45RO + /TILs High group was significantly higher than that of the CD45RO + /TILs Low group ( p < 0.05).
A high ratio of CD45RO-expressing TILs was associated with a disease-free/overall survival improvement in OSCC patients. Furthermore, the number of TILs that express CD45RO was associated with the expression of MICA in tumors. These results suggest that CD45RO-expressing TILs are useful biomarkers for OSCC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。